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Abstract
Retinitis Pigmentosa (RP) is a heterogeneous group of inherited retinal dystrophies characterised ultimately by the loss of
photoreceptor cells. RP is the leading cause of visual loss in individuals younger than 60 years, with a prevalence of about 1
in 4000. The molecular genetic diagnosis of autosomal recessive RP (arRP) is challenging due to the large genetic and
clinical heterogeneity. Traditional methods for sequencing arRP genes are often laborious and not easily available and a
screening technique that enables the rapid detection of the genetic cause would be very helpful in the clinical practice. The
goal of this study was to develop and apply microarray-based resequencing technology capable of detecting both known
and novel mutations on a single high-throughput platform. Hence, the coding regions and exon/intron boundaries of 16
arRP genes were resequenced using microarrays in 102 Spanish patients with clinical diagnosis of arRP. All the detected
variations were confirmed by direct sequencing and potential pathogenicity was assessed by functional predictions and
frequency in controls. For validation purposes 4 positive controls for variants consisting of previously identified changes
were hybridized on the array. As a result of the screening, we detected 44 variants, of which 15 are very likely pathogenic
detected in 14 arRP families (14%). Finally, the design of this array can easily be transformed in an equivalent diagnostic
system based on targeted enrichment followed by next generation sequencing.
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Introduction
Retinitis pigmentosa (RP, OMIM 26800) is a heterogeneous
group of inherited retinal dystrophies caused by the progressive
loss of photoreceptors. Typically it presents with poor night vision
in early or middle life, followed by the constriction of the visual
field and progressive loss of visual acuity leading to complete
blindness after several decades. On ophthalmic examination, RP
manifests with retinal pigmentation, attenuated retinal blood
vessels, and waxy optic disc pallor associated with a diminished or
abolished electroretinogram. Prevalence of nonsyndromic RP is
approximately 1 in 4000 [1]. The condition may segregate as an
autosomal dominant RP (24%), autosomal recessive (41%), or an
X-linked recessive trait (22%), and the remaining 12% of cases
were presumed to result from non-genetic factors, non-Mendelian
inheritance (for example mitochondrial or de novo mutations) or
complex inheritance (digenic or polygenic inheritance) [2].
To date, 37 loci have been reported being responsible for
autosomal recessive RP (arRP), of which 34 genes have been
identified [3]. However, all together the reported loci are
responsible for only ,35–45% of the recessive RP cases, none
of them independently account for a substantial proportion of
arRP cases [4]. Recently, we have identified a new gene as the
most common single gene that causes arRP: Eyes Shut Homologue
(EYS; 15.9% of cases) [5], almost all causal mutations associated
with arRP are rare (minor allele frequency (MAF) ,,0.01) and
most of the associated genes have hundreds of disease alleles with
potentially different pathogenic effects [2].
The identification of a causative mutation is important to
ascertain the genetic basis of the disease, and thus paves the way
for genetic counselling, family planning and future gene-targeted
treatment. Nevertheless, further strategies such as establishing a
classification of the mutations as loss- or gain-of-function and
assessing the functionality of the mutant proteins, should be
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undertaken to develop a treatment tailored to each of the different
arRP genes.
Molecular diagnosis of arRP mutations is challenging because a
large number of deleterious mutations can be found in each gene,
and multiple genes can be mutated to give the same phenotype.
Thus, the extensive genetic and allelic heterogeneity of retinal
dystrophies makes mutation detection by current molecular
techniques problematic. Pre-screening tools, such as single-strand
chain polymorphism and denaturing high-pressure liquid chro-
matography are economic techniques capable of detecting known
changes, but not to identify new ones. Similarly, there are
commercial genotyping microarrays available, based on the
arrayed primer extension (APEX) technology [6], which enable
the simultaneous screening of multiple genes but they can only
detect a fixed number of known mutations. However, the extensive
genetic heterogeneity along with the still unknown repertoire of
arRP mutations requires of the use of a tool that can identify both,
known and new mutations, in a large number of genes in a fast
manner. Dideoxy sequencing method can identify mutations but
its use for the screening of multiple genes is so time-consuming and
expensive that is inapplicable in this scenario. Recently, emerging
technologies for ultra high throughput sequencing have started to
be applied to diagnostic in a prospective manner [7], [8].
However, the use of these technologies for screening a set of
disease causing genes is still limited because of the perceived
technical and data-handling challenges. Targeted resequencing
offers a solution of compromise that can have a practical
application in clinics. Nevertheless, the use of a capture system
for the enrichment of the target sequences, followed by ultra-high
throughput sequencing, is still a complex technology not available
in many laboratories and with many problems of standardisation
that needs still to be solved. There are, though, alternative
approaches that can be used while the new sequencing
technologies become applicable in this context. Thus, while the
past decade has witnessed the development of sequencing by
hybridization to oligonucleotides on an array [9], recently
significant improvements have been made in this technology,
and resequencing microarrays offer the potential of determining
the sequence of a large number of genes with a reasonable amount
of effort and cost [10]. Herein, we present the development and
validation of a custom design resequencing microarray which
allows a widespread screening of both, novel and known
mutations, in 16 genes related to arRP. Although this technology
has already been used as a diagnostic test to investigate arRP [10–
13], this is the first report of the application of these resequencing
platforms which involves the study of the most prevalent gene,
EYS. A cohort of 102 arRP patients from Spain was screened with
the new RP genechip, demonstrating the potential clinical utility of
this technology.
Methods
Ethics Statement
The study conformed to the tenets of the declaration of Helsinki
(Edinburgh, 2000) and was approved by the Institutional Review
Board of the Hospital Virgen del Rocı´o, Seville. An informed
consent form was signed by all participants for clinical and
molecular genetic studies.
Subjects and Clinical Data
The study cohort comprises 102 Spanish unrelated patients
affected by arRP. A full ophthalmic examination was performed as
described elsewhere [14]. RP was defined as bilateral visual loss,
initial hemeralopy, restriction of visual field, gradual increased
bone spicule pigmentation and decrease of visual acuity,
attenuation of retinal vessels, reduced or undetectable electroret-
inogram (ERG) and waxy disc pallor. Globally, our cohort
included 98 arRP patients with no known mutations and 4 arRP
patients with 4 pathogenic variants included as positive controls of
mutations, previously identified by dideoxy sequencing (Table 1).
In addition, available samples of proband family members were
tested for co-segregation studies. A group of 100 control
individuals was also recruited which comprised unselected,
unrelated race-, age-, and gender-matched individuals from Spain.
Custom Genome Resequencing Microarray Design
The sequences comprising all coding exons plus 15 bp of
flanking intronic sequence from the arRP genes CERKL, CNGA1,
CRB1, EYS, IDH3B, LRAT, MERTK, NR2E3, PDE6B, PRCD,
PROM1, RGR, RHO, RLBP1, RPE65 and TULP1 were selected to
tile on the resequencing microarray (Affymetrix, Santa Clara, CA).
Repetitive elements and internal duplications that may lead to
cross hybridization were identified by using Repeat Masker [15]
and deleted. For each position of the interrogated sequence, eight
25-mer probes are represented on the array: four probes for each
strand, each with a different nucleotide in the middle (A,G,C,T)—
one perfect match for the reference sequence and three
mismatches—allowing the detection of all possible nucleotide
Table 1. Known Sequence Changes Tested in the Validation and Reproducibility assay.
Family ID Gene
Nucleotide change
Protein change
Genotype
Mutation
Type
Calls of the arrays using the
IUPAC Base Code* Reference
RP 21 TULP1 c.823-4A.G
Heterozygous
Splice site mutation Detected as R [37]
RP 242 TULP1 c.430A.G
p.K96E
Heterozygous
Missense Detected as R Unpublished
RP 57 TULP1 c.1255C.G
p.R419G
Heterozygous
Missense Detected as S Unpublished
RP 60 EYS c.78-79insGC
p.Q27RfsX16
Heterozygous
Insertion frameshift Not Detected [5]
*IUPAC Base Codes: The symbol R to designate PuRine (A or G); S to designate Strong interaction (C or G).
doi:10.1371/journal.pone.0027894.t001
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substitutions of both strands. In total, 45,096 bp features are tiled
on the array and 44,282 bp of double-stranded gene sequences are
analyzed. The remaining oligonucleotides represent control DNA
(Affymetrix control reference sequence; AFFX-TagIQ-EX). Our
custom designed arRP chips were fabricated by Affymetrix using
standard photolithography and solid-phase DNA synthesis [9],
[16], [17].
Experimental Procedure and Data Analyses
A total of 93 polymerase chain reaction (PCR) amplicons
(ranging from 300 bp to 7.5 Kbp) were designed and optimized to
amplify under a common set of Short-Range and Long-Range
PCR conditions. Primer sequences and PCR conditions employed
are available upon request. DNA concentration of each amplicon
was measured using a picogreen assay and PCR products were
pooled and purified of residual primers and nucleotides using
Clontech purification plates (Clontech, Mountain View, CA). The
DNA was then fragmented, labeled with biotin, and hybridized to
the chip for 16 hours at 49uC rotating at 60 rpm according to
manufacturer’s protocols (GeneChip CustomSeq Resequencing
Array Protocol, Vers.2; Affymetrix, Santa Clara, CA). The arrays
were subsequently washed and stained on a fluidics station
followed by the scanning on a GeneChip 3000 Scanner
(Affymetrix, Santa Clara, CA), and the raw data were analyzed
using Affymetrix GeneChip Resequencing Analysis Software
(GSEQH v4.0) which enabled alignment of patients sequences
against a reference sequence. All array data is MIAME compliant,
and the raw data has been deposited in EBI Array Express
database, a MIAME compliant database as detailed on the
MGED Society website [18] under accession number E-MTAB-
786.
The novel identified variants were subsequently verified and
screened in healthy controls by dideoxy sequencing and if
additional family members were available, segregation of the
variant with the disease was assessed (Figure 1).
In order to evaluate the pathogenicity of the novel variants, we
analysed the potential impact of a given variant on the function or
structure of the encoded protein based on conservation, physical
properties of the amino acids, or in its possible occurrence in
regulatory or splicing motifs using the software PupaSuite [19],
[20]. To study the EYS variants, the domain architecture
prediction and the alignment of the different orthologs were
performed using bl2seq (NCBI) and EMBOSS Pairwise Alignment
Algorithms: Needle and Water (EBI) alignments. The fully
characterised SPAM proteins were aligned using MUSCLE
(Multiple Sequence Comparison by Log-Expectation) program
at EBI (For more details on the EYS bioinformatic characterization
see [5]).
MLPA Analysis of the EYS Gene
To clarify the molecular genetic cause in those families with just
a single heterozygotic detected change in EYS, MLPA (Multiplex
Figure 1. Analytic workflow. A. Genechip resequencing analysis software output for of the exon 8 of CERKL for 1 sample (index patient of the
Family RP76) compared to reference sequence using GSEQ. The chip data reveals a nonsense mutation in CERKL (c.769C.T; p.R257X) at position 268
in the tiled sequence. The reference sequence carries a homozygous C in that position. The intensity histogram below shows how the mutant sample
with a homozygous T binds most strongly to the probe with A on the forward strand and T on the reverse one. B. Electropherogram depiction of the
members of the family RP76 confirming the co-segregation of the variant with the disease.
doi:10.1371/journal.pone.0027894.g001
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Ligation Probe Amplification) was performed to identify the
second variant as an alternative approach to screen for copy
number variations (CNVs), given that these type of mutations are
particularly frequent in this gene [14]. Thus, 4 of the arRP patients
were analysed by MLPA and gene dosage variations on EYS were
evaluated as described elsewhere [14].
Results
Validation of the Array: Assessment of Positive Controls
The PCR of 3 out of the 93 amplicons (3.2%) could not be
optimized; therefore, hybridization failed and these exons were
excluded from further analysis. The average call rates for
successfully hybridized amplicons were of 92% for the 102 arrays.
Several algorithm parameters regarding this base calling can be
altered, affecting the call rate and accuracy of the base calls [16].
The highest call rate was obtained using a Quality Score
Threshold (QST) of 2 and without Base Reliability Threshold
(BRT) [21]. Therefore, these settings were used for the call rate
assessment. In addition, we observed a call rate constant
improvement as the number of experiments increased. GSEQ
contains a learning algorithm derived from ABACUS, an
adaptative background genotype calling scheme to optimize data
from multiple arrays analyzed together; larger batch sizes in an
analysis are thus expected to have greater accuracy [22], [23]. The
no-calls regions are mainly observed in G-C rich areas and
repetitive elements unsuitable for analysis (ie, SINE, LINE, ALU,
etc). PDE6B and CERKL were particularly rich in such unread
nucleotides. So far, no arRP mutations have been reported in such
regions [24].
To determine the ability of our chip to detect different types of
mutations, we processed the DNA of 4 arRP patients carrying
known mutations in 2 of the genes tiled onto the array (Table 1).
The arrays used in this study were not designed to specifically
identify deletions or insertions and, as expected, the insertion that
was in a heterozygous state could not be detected by the GSEQ
software. However, the substitution variants were detected.
Variants Identified by the arRP Array
A total of 42 sequence changes were identified by the arRP
arrays, of which 13 were potentially pathogenic variants affecting
14 out of the 98 patients (14%) (Table 2). Briefly, 5 of the 13
changes detected were known mutations comprising 1 nonsense
substitution: p.R257X in CERKL (Figure 1) present in two
unrelated families, 3 missense mutations: p.C948Y in CRB1,
p.S297R and p.T342M in RHO and 1 acceptor site mutations:
c.1297-2A.G in MERTK, whereas the other 8 potentially
pathogenic variants were novel sequence changes: 6 missense
and 2 splice site variants, all of them absent in control population.
The potentially pathogenic variants were detected in 10 of the 16
retinal disease genes tiled on the array.
Regarding the missense novel mutations, comparison between
the orthologs from different species revealed a high level of
conservation in 5 out of the 6 substituted residues: Ile384 in
CNGA1, Ile1232 and Cys2668 in EYS, Thr292 in RLBP1 and
Arg180 in TULP1 (Figure 3). In addition, bioinformatic tools
employed to evaluate both the impact of the novel sequence
changes on the transcription or translation mechanisms predicted
that 2 of the missense variants were possibly damaging (p.I384T in
CNGA1 and p.R180H in TULP1), 2 of them were shown to abolish
the splicing acceptor site (c.5928-2A.G in EYS and c.726-3C.A
in RPE65), and 1 disulfide bond of the EYS/SPAM structure
seemed to be compromised by the amino acidic substitution of a
Cysteine to a Phenylalanine in the position 2668.
The 13 identified potentially pathogenic sequence changes were
present in 14 out of the 98 patients included in this study. Of them,
5 patients were homozygous for the mutation and the 9 remainder
Table 2. Potentially pathogenic variants detected by the arRP Array and the MLPA.
Family ID Gene Nucleotide change
Amino acid
change Novel/Reference
Control population
studies (mutant/normal
alleles) Genotype
RP 76 CERKL c.769C.T p.R257X [34] - Homozygous
RP 206 CERKL c.769C.T p.R257X [34] - Homozygous
RP 95 CNGA1 c.1151T.C p.I384T Novel{ 0/200 Heterozygous
RP 29 CRB1 c.2843G.A p.C948Y [38] - Homozygous
RP 234 EYS c.3695T.C p.I1232T Novel 0/200 Heterozygous
RP 234 EYS c.1767-?_2023+?del p.C590YfsX4 [26] - Heterozygous
RP 234 EYS c.1971delT p.S658VfsX4 [26] - Heterozygous
RP 109 EYS c.5928-2A.G - Novele 0/200 Heterozygous
RP 202 EYS c.8003G.T p.C2668F Novel* 0/200 Heterozygous
RP 96 MERTK c.1297-2A.G - [39] - Homozygous
RP 353 PROM1 c.1532C.A p.T520K Novel 0/200 Heterozygous
RP 242 RHO c.891C.T p.S297R [40] - Heterozygous
RP 322 RHO c.1025C.T p.T342M [41] - Homozygous
RP 108 RLBP1 c.875A.T p.T292M Novel 0/200 Heterozygous
RP 193 RPE65 c.726-3C.A - Novele 0/200 Heterozygous
RP 333 TULP1 c.539G.A p.R180H Novel{ 0/200 Heterozygous
*Disulfide Bond Alteration predicted by Dianna 1.1.
{Predicted as possibly damaging by Polyphen (V1).
eSplicing site Mutation by Berkeley Drosophila Genome Project (BDGP) website [42], [43].
doi:10.1371/journal.pone.0027894.t002
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were heterozygous. For patients with a single heterozygotic
potentially pathogenic variant, further analyses of genetic variants
not detectable by our customized resequencing chip would be
valuable for the detection of the second mutation in arRP genes.
The remaining 29 detected sequence changes comprised 9
amino acid substitutions, 1 59UTR variant, 6 synonymous
changes, and 13 intronic variants that do not have any predicted
deleterious effect on splicing, can be considered as unreported
SNPs (Table S1). Among the novel nonsynonymous changes,
p.G618S in EYS was initially reported as disease-causing variant
[25], but the segregation studies results in the Spanish family
discarded their pathogenic role. The detection of these SNPs is a
good validation test for the array as it illustrates the ability of the
chip to detect single base pair substitutions
MLPA Analysis of the EYS Gene
The present study led to the identification of one intragenic EYS
rearrangement in the family RP 234 that carries a novel very likely
pathogenic change (p.I1232T, absent in controls). MLPA analysis
revealed 0% dosage in exon 12 of EYS whereas 50% dosage was
shown in the adjacent intron 12. The resequencing data of that
exon showed an apparently normal readout suggesting that at least
one allele is present. This situation could be explained by the co-
existence of two independent pathogenic events occurring in
different alleles. One of them is the heterozygous deletion of the
exon12-intron12, and the other one would be an underlying defect
on the DNA sequence where the MLPA probe should hybrid. As
we expected, further dideoxy sequencing showed a homozygous
deletion of 1 bp disabling the correct hybridization of the MLPA
probe (Figure 2). It is noteworthy that both the large deletion
(c.1767-?_2023+?del; p.C590YfsX4) and the 1 bp deletion
(c.1971delT; p.S658VfsX4) are known mutations previously
described by our group in other unrelated RP families [14], [26]
(Table 2).
In an attempt to define a characteristic profile that may detect
these heterozygous mutations by our resequencing approach, the
Figure 2. Mutations identified in the RP 234 family using several detection approaches. A. Schematic representation of the MLPA
hybridization probe regions of EYS exons 11–14. The asterisks show the location of the mutations and how they affect the hybridization process. The
MLPA dosage readouts and the fragment sizes for the exon-intron 12 are also represented in a box. B. Resequencing trace graph of the five bases
interval including the mutated single nucleotide (c.1971delT). Forward and reverse strands correspond to each of the patient alleles. Manual
examination of signal intensity data (Y axis) is coherent with the two mutations. The asterisk points the deleted base in the forward allele. The
intensity in reverse strand is 10-fold lower than forward (circle in red) suggesting that this allele is deleted (c.1767-?_2023+?del). C. Dideoxy
sequencing electropherogram of exon 12 of the index patient confirming the deletion of a T (c.1971delT).
doi:10.1371/journal.pone.0027894.g002
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intensity signal of each strand was evaluated. Forward and reverse
strands correspond to each of the patient alleles. The results of the
manual interrogation were coherent with the two mutated alleles.
The deleted T appeared as an unclear nucleotide in the forward
strand whereas the deletion of the whole allele manifested as a
drop in the intensity signal in the reverse strand (Figure 2).
Discussion
Molecular diagnosis of RP is a challenging task given the huge
genetic heterogeneity of this disease. The large number of
deleterious mutations that can be found in each gene, and the
multiple genes that can be mutated to give the same phenotype,
make the detection of mutations by traditional screening methods
costly and time consuming. Thus, there is an urgent need for a
validated screening method that allows the detection of mutations
simultaneously in several genes in a single high-throughput
platform. Microarray sequencing technology offers a rapid method
for detecting mutations in patients with genetically heterogeneous
diseases such as arRP. Using the resequencing technology to read
comprehensive nucleotide sequence of a number of genes presents
some advantages in comparison with other available techniques.
The resequencing chip is 5 to 10 times less expensive than
conventional sequencing [12] and although the APEX array is
cheaper, the resequencing chip provides the significant benefit of
detecting novel variants.
The detection of known and novel mutations in this study
establishes array-based resequencing as an effective tool with
potential to improve diagnosis, which hopefully may help to
provide genetic counselling and give a more reliable prognosis in
patients and their families.
Mutational screening of arRP patients using resequencing
array-based technology has been previously reported [11–13],
but our arRP sequencing array offers for the first time an
opportunity to screen for sequence alterations in the EYS gene.
The high number of EYS mutations detected by PCR based direct
dideoxy genomic sequencing published in different arRP patients
and the diverse ethnic origins of these families [5], [25–30] set this
gene as the most prevalent one in arRP (15.9% in Spanish families)
[5]. The combination of the large size of this gene and the lack of
hot spots of disease-causing mutations make the screening of this
gene using traditional methods slow and expensive, but these
disadvantages can now be overcome by the implementation of the
array-based resequencing technology.
The call rates for the arrays in this study (92%) are within the
range of previous studies (90–99%). Considering that this study
utilised higher numbers of arrays than previous studies, we would
have expected the call rates to be higher but the main problem here
was due to hybridization failures resulting in no-called regions.
Certain probes as those with higher than average GC content or
those containing repeat regions can be problematic for resequencing
arrays and are more likely to be no-called. Analysis of the sequence
on RepeatMasker revealed that some regions of the genes CNGA1,
TULP1 and PDE6B are particularly rich in repeat sequences
resulting in decreased signal and increased chance of being no-
called. Extreme caution must be exerted in designing the probes
content of the chip in order to avoid a call rate decrease.
The arRP chip reported herein can screen for most known
disease causing mutations due to single nucleotide changes but as
expected, heterozygous deletions, insertions and CNVs have been
the main problem for the array. In part, some of these limitations
can be overcome with improvements in the chip design like
including specific probes for known insertions and deletions [21],
[31], [32] but they only allow the detection of known changes and
it would be convenient to periodically update the resequencing
design with newer insertions and deletions. For that reason and for
the high prevalence of CNVs recently reported in the EYS gene in
Spanish families [14], we decided to use the MLPA technology in
those families where only one pathogenic change had been
identified by the resequencing approach in that gene. Despite the
reduced number of families included on the MLPA study, the
results obtained were very interesting and allowed the identifica-
tion of two independent pathogenic events in one patient (Family
RP 234) affecting two different alleles. These results evidenced that
the MLPA technique is able to detect not only CNVs but also
short deletions of 1 bp if they are located within the hybridization
region of the probe. In our opinion, the combination of the two
screening strategies is currently the most rapid and efficient
method for mutation screening of arRP in clinical practice.
Regarding the family RP 234, a third heterozygous variant was
detected in the EYS gene (c.3695T.C; p.I1232T) absent in
controls and evolutionarily conserved. Possibly, this variation could
represent a rare SNP but also a mutation that may modify the
phenotype. Such mechanisms involving the presence of modifier
alleles have been suggested to explain variability in disease
phenotype among affected family members with retinal dystrophies
[33]. Great caution must be exerted when interpreting the
functional effect of such novel variants and a more comprehensive
study in additional members of the family would reveal them to be
disease causing, modifier or polymorphic variants.
In addition to mutations detected in the genes routinely tested
for arRP, we identified two mutations (p.T342M and p.S297R)
typically associated with autosomal dominant cases of RP (adRP)
in the rhodopsine gene, Rho. This evidenced that Rho not only
plays an important role in the pathogenesis of adRP, but it is also
involved in a number of arRP cases and its routine analysis in
those families should be considered.
Most of the RP associated genes have hundreds of disease alleles
but sometimes one predominates. A few examples are the
deleterious c.769C.T allele of CERKL that causes a substantial
proportion of sporadic and arRP Spanish cases [34], [35], and the
c.2688T.A allele of CRB1 described as a frequent mutation by
Vallespin et al. [36]. The EYS variants c.1971delT and c.1767-
?_2023+?del have also been detected in unrelated Spanish and
French families [14], [26]. Yet haplotype analyses would be
valuable to determine the origin of these mutations, identifying
recurrent mutations in Caucasian and especially specific popula-
tions such as the Spanish one provides an essential source for the
molecular and clinical diagnosis of such a heterogeneous disease.
Although further refinements in array design, analysis algo-
rithms or both would need to be performed to improve this tool
and optimise research translation into the clinical setting, this work
shows that resequencing array-based technology can be used as a
rapid screening tool. The large amount of data generated by this
high-throughput methodology is an estimable resource not only
for the establishment of genotype-phenotype correlations, but also
for the identification of modifier alleles that could be responsible of
the significant phenotypic variability of RP. Furthermore, this
technology has provided new information and enhances our
Figure 3. ScanProsite predicted domains of the proteins and ClustalW alignment of the orthologs from different species. A. CNGA1
(p.I384T). B. EYS (p.I1232T). C. EYS (p.C2668F). D. PROM1 (p.T520K). E. RLBP1 (p.T292M). F. TULP1 (p.R180H).To study the EYS variants, we have used
the orthologs alignment performed in Barragan et al. [5]. The residue highlighted is mutated.
doi:10.1371/journal.pone.0027894.g003
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understanding of the aetiology and pathogenesis of such as
genetically heterogeneous disease, and ultimately may lead to
better clinical management of patients and their families.
Finally, the design of this array can easily be transformed in an
equivalent diagnostic system based on targeted enrichment
followed by next generation sequencing.
Supporting Information
Table S1 Unlikely but unknown pathogenic coding variants
detected by the arrp array.
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